Your browser doesn't support javascript.
loading
Trends in lung cancer survival in the Nordic countries 1990-2016: The NORDCAN survival studies.
Lundberg, Frida E; Ekman, Simon; Johansson, Anna L V; Engholm, Gerda; Birgisson, Helgi; Ólafsdóttir, Elínborg J; Mørch, Lina Steinrud; Johannesen, Tom Børge; Andersson, Therese M-L; Pettersson, David; Seppä, Karri; Virtanen, Anni; Lambe, Mats; Lambert, Paul C.
Afiliação
  • Lundberg FE; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address: frida.lundberg@ki.se.
  • Ekman S; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Medical Unit Head-Neck-Lung-Skin Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden. Electronic address: simon.ekman@ki.se.
  • Johansson ALV; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Cancer Registry of Norway, Oslo, Norway. Electronic address: anna.johansson@ki.se.
  • Engholm G; Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark. Electronic address: gerda@cancer.dk.
  • Birgisson H; Icelandic Cancer Registry, Reykjavík, Iceland. Electronic address: helgi.birgisson@krabb.is.
  • Ólafsdóttir EJ; Icelandic Cancer Registry, Reykjavík, Iceland. Electronic address: ella@krabb.is.
  • Mørch LS; Danish Cancer Institute, Cancer Surveillance and Pharmacoepidemiology, Danish Cancer Society, Copenhagen, Denmark. Electronic address: morch@cancer.dk.
  • Johannesen TB; Cancer Registry of Norway, Oslo, Norway. Electronic address: tom.borge.johannesen@kreftregisteret.no.
  • Andersson TM; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: therese.m-l.andersson@ki.se.
  • Pettersson D; Swedish Cancer Registry, National Board of Health and Welfare, Stockholm, Sweden. Electronic address: david.pettersson@socialstyrelsen.se.
  • Seppä K; Finnish Cancer Registry, Helsinki, Finland; Faculty of Social Sciences, Tampere University, Tampere, Finland. Electronic address: karri.seppa@cancer.fi.
  • Virtanen A; Department of Pathology, University of Helsinki, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland. Electronic address: anni.virtanen@hus.fi.
  • Lambe M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Regional Cancer Centre Uppsala Central Sweden, Uppsala, Sweden. Electronic address: mats.lambe@ki.se.
  • Lambert PC; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, UK.
Lung Cancer ; 192: 107826, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38795460
ABSTRACT

OBJECTIVES:

The aim of this study was to evaluate if the previously reported improvements in lung cancer survival were consistent across age at diagnosis and by lung cancer subtypes. MATERIALS AND

METHODS:

Data on lung cancers diagnosed between 1990 and 2016 in Denmark, Finland, Iceland, Norway and Sweden were obtained from the NORDCAN database. Flexible parametric models were used to estimate age-standardized and age-specific relative survival by sex, as well as reference-adjusted crude probabilities of death and life-years lost. Age-standardised survival was also estimated by the three major subtypes; adenocarcincoma, squamous cell and small-cell carcinoma.

RESULTS:

Both 1- and 5-year relative survival improved continuously in all countries. The pattern of improvement was similar across age groups and by subtype. The largest improvements in survival were seen in Denmark, while improvements were comparatively smaller in Finland. In the most recent period, age-standardised estimates of 5-year relative survival ranged from 13% to 26% and the 5-year crude probability of death due to lung cancer ranged from 73% to 85%. Across all Nordic countries, survival decreased with age, and was lower in men and for small-cell carcinoma.

CONCLUSION:

Lung cancer survival has improved substantially since 1990, in both women and men and across age. The improvements were seen in all major subtypes. However, lung cancer survival remains poor, with three out of four patients dying from their lung cancer within five years of diagnosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article